NCT00630084View on ClinicalTrials.gov

Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Chronic Hepatitis CNeoplasms
Interventions
DRUG

pegylated interferon alpha 2a and plus ribavirin

pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks

DRUG

pegylated interferon alpha 2a and plus ribavirin

pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks

Trial Locations (1)

807

Kaohsiung Medical University Hospital, Kaohsiung City

All Listed Sponsors
lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT00630084 - Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter